Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function

American Journal of Clinical Nutrition

Volumn 80, Issue 6, 2004, Pages 1618-1625

  Braat, Henri ^a,c   Van Den Brande, Jan ^a   Van Tol, Erik ^b   Hommes, Daan ^a   Peppelenbosch, Maikel ^a   Van Deventer, Sander ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NUMICO RESEARCH   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Crohn disease; Dendritic cells; Hyporesponsiveness; Lactobacillus rhamnosus; T cells

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROBIOTIC AGENT;

ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS RHAMNOSUS; MEMORY CELL; MONOCYTE; NONHUMAN; T LYMPHOCYTE; ADULT; BIOSYNTHESIS; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; LACTOBACILLUS; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY;

BACTERIA (MICROORGANISMS); LACTOBACILLUS RHAMNOSUS;

ADULT; ANTIGENS, CD28; ANTIGENS, CD3; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CROHN DISEASE; CYTOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LACTOBACILLUS; MALE; MIDDLE AGED; MONOCYTES; PROBIOTICS;

EID: 16544392923     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/80.6.1618     Document Type: Article

References (36)

1. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39: 237-8.
2. Borriello SP, Hammes WP, Holzapfel W, et al Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-80.
3. Marteau P. Role of the intestinal flora in gastrointestinal diseases. Lancet 2000;356(suppl):s28.
4. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
5. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10- deficient mice. Inflamm Bowel Dis 2002;8:71-80.
6. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
7. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869-71.
8. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-9.
9. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35: 483-9.
10. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-50.
11. Tuomola EM, Ouwehand AC, Salminen SJ. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol 1999;26:137-42.
12. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 2002;82:279-89.
13. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580-91.
14. Shanahan F. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr 2002;88(suppl 1):S5-9.
15. Pochard P, Gosset P, Grangette C, et al. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. J Allergy Clin Immunol 2002;110:617-23.
16. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
17. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
18. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
19. Appleman LJ, Boussiotis VA. Tcell anergy and costimulation. Immunol Rev 2003;192:161-80.
20. Braat H, De Jong EC, Van Den Brande JM, et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med 2004;82:197-205.
21. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
22. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
23. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389: 737-42.
24. + regulatory T cells and IL-10. J Immunol 2003;171:971-8.
25. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
26. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
27. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94.
28. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-10.
29. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A 1992;89:421-5.
30. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-14.
31. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 Tcells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98:70-7.
32. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003;18:155-67.
33. Boris S, Jimenez-Diaz R, Caso JL, Barbes C. Partial characterization of a bacteriocin produced by Lactobacillus delbrueckii subsp. lactis UO004, an intestinal isolate with probiotic potential. J Appl Microbiol 2001;91:328-33.
34. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003;94:449-55.
35. Rogelj I, Bogovic Matijasic B, Canzek Majhenic A, Stojkovic S. The survival and persistence of Lactobacillus acidophilus LF221 in different ecosystems. Int J Food Microbiol 2002;76:83-91.
36. Smits HH, van Beelen AJ, Hessle C, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004;34(5): 137-80.